{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-007944","form_type":"8-K","ticker":"IONS","cik":"0000874015","company_name":"IONIS PHARMACEUTICALS INC","filed_at":"2023-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.333382+00:00","generated_at":"2026-06-19T06:01:39.489859+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ionis reports FY2022 revenue $587M, net loss $270M; eplontersen NDA submitted; 2023 guidance revenue >$575M","bullets":["FY2022 total revenue $587M (down from $810M in 2021); net loss $270M vs $29M loss in 2021.","Q4 2022 revenue $152M, net loss $52M; non-GAAP net loss $168M.","Eplontersen NDA submitted to FDA for ATTRv-PN; tofersen under FDA/EMA review; olezarsen Fast Track for FCS.","2023 guidance: revenue >$575M, non-GAAP operating expenses ~$970-995M, net operating loss <$425M.","Cash, cash equivalents and short-term investments $2.0B at Dec 31, 2022; plus $500M from Royalty Pharma in Jan 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-007944","json":"https://secwatch.observer/filing/0001140361-23-007944.json","markdown":"https://secwatch.observer/filing/0001140361-23-007944.md","text":"https://secwatch.observer/filing/0001140361-23-007944.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874015/000114036123007944/0001140361-23-007944-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874015/000114036123007944/brhc10048570_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T06:01:39.489859+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b7c681918ba54cfc5067bea0edef16a42107fe01","claim":"IONIS PHARMACEUTICALS INC reported financial results for the fourth quarter and full year ended December 31, 2022.","evidence_excerpt":"On February 22, 2023, Ionis Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing the Company’s financial results for the quarter and fiscal year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/874015/000114036123007944/0001140361-23-007944-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}